TNF and melanoma: Similarly, daily injection of a CD13-specific VHH single-domain antibody fused to a mutated (Y86F) single-chain murine TNF (50 μg/mouse) could selectively activate the tumor neovasculature in a murine melanoma model without detectable toxicity [70,71].